We are proud to welcome BICO as a new member of the SACC-NE network!
/
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, BICO enables their customers to improve people's health and lives for the better.
1. Tell us about BICO.
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company. Through the combination of advanced engineering, cutting edge software development, and biology the Group looks to enable their customers to create the future of health.
At BICO, the group companies provide technologies that enable smart and connected workflows, catalyzing the paradigm shift to Health 4.0. A shift that is taking place across key ecosystems like tissue engineering, diagnostics, cell line development, and multi-omics.
The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO.
2. Share some exciting news about BICO.
Over the last 12 months, BICO has gone through an exciting period of growth fueled by mergers and acquisitions. Strengthening our foundation in providing exciting hardware and software solutions, like 3D bioprinters, live-cell imagers, and automation solutions to the wider life science community. With companies based in Gothenburg, Berlin, Boston, and San Diego the BICO group has a truly global reach and we are extremely excited to continue to expand in these territories.
3. Why did you join SACC-NE?
BICO is thrilled to be a part of the SACC-NE. With an ever-expanding operation in the United States, we look forward to working with fellow members, making meaningful connections that will drive forward our business and support us on the journey to create the future of health. We are also tremendously excited by the busy event calendar that the organization has and as a result, the many opportunities to increase awareness around the BICO brand.
4. What do you look forward to in 2022?
In 2022 we look forward to continuing to explore the synergies between the companies that are in the BICO group to develop products and services that continue to elevate how our customers work. With our latest acquisition on December 16th, 2021, we will also be looking forward to kicking off our 2022 with an onboarding exercise and getting to know our new colleagues better.
5. Where do you see BICO in five years?
BICO in 5 years certainly has the potential to be one of the most influential players in the life sciences industry and it is certainly something that we firmly believe we will achieve. In addition to this, we see BICO being one of the leading technology providers within key application areas like cell line development, tissue engineering, multi-omics, and diagnostics.
